Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ATAI Life Sciences NV ATAI

Healthcare Biotechnology
ATAI Life Sciences NV is a Germany-based clinical-stage biopharmaceutical company. The Company engages in developing various treatments that focuses on various mental health disorders. The Company's therapeutic lead compound include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B... see more

Recent & Breaking News (NDAQ:ATAI)

atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression

GlobeNewswire January 6, 2023

atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101

GlobeNewswire December 23, 2022

atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia

GlobeNewswire December 19, 2022

The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital

GlobeNewswire December 16, 2022

atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer

GlobeNewswire November 29, 2022

atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment

GlobeNewswire November 17, 2022

atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update

GlobeNewswire November 10, 2022

Women in Psychedelics Announces atai as Platinum Sponsors

Business Wire November 4, 2022

atai Life Sciences to Participate in November Investor Events & Healthcare Conferences

GlobeNewswire November 1, 2022

atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update

GlobeNewswire November 1, 2022

atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression

GlobeNewswire October 25, 2022

atai Life Sciences Announces R&D Day Agenda

GlobeNewswire October 20, 2022

atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology

GlobeNewswire October 18, 2022

IntelGenx's Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an Oral Thin Film Psychedelic Drug Candidate

GlobeNewswire October 13, 2022

atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD

GlobeNewswire October 12, 2022

atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT

GlobeNewswire October 5, 2022

atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day

GlobeNewswire October 4, 2022

atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01

GlobeNewswire September 27, 2022

atai Life Sciences to Participate in September Investor Events

GlobeNewswire September 6, 2022

atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update

GlobeNewswire August 15, 2022